Please use this identifier to cite or link to this item:
|Title:||Point-of-care measurement of blood lactate in children admitted with febrile illness to an African District Hospital|
Ilse C E Hendriksen
National Institute for Medical Research Tanga
London School of Hygiene & Tropical Medicine
Kilimanjaro Christian Medical Centre
|Citation:||Clinical Infectious Diseases. Vol.53, No.6 (2011), 548-554|
|Abstract:||Background.Lactic acidosis is a consistent predictor of mortality owing to severe infectious disease, but its detection in low-income settings is limited to the clinical sign of "deep breathing" because of the lack of accessible technology for its measurement. We evaluated the use of a point-of-care (POC) diagnostic device for blood lactate measurement to assess the severity of illness in children admitted to a district hospital in Tanzania.Methods.Children between the ages of 2 months and 13 years with a history of fever were enrolled in the study during a period of 1 year. A full clinical history and examination were undertaken, and blood was collected for culture, microscopy, complete blood cell count, and POC measurement of blood lactate and glucose.Results.The study included 3248 children, of whom 164 (5.0%) died; 45 (27.4%) of these had raised levels of blood lactate ( > 5 mmol/L) but no deep breathing. Compared with mortality in children with lactate levels of ≤3 mmol/L, the unadjusted odds of dying were 1.6 (95% confidence interval [CI],.8-3.0), 3.4 (95% CI, 1.5-7.5), and 8.9 (95% CI, 4.7-16.8) in children with blood lactate levels of 3.1-5.0, 5.1-8.0, or > 8.0 mmol/L, respectively. The prevalence of raised lactate levels ( > 5 mmol/L) was greater in children with malaria than in children with nonmalarial febrile illness (P < . 001) although the associated mortality was greater in slide-negative children.Conclusions.POC lactate measurement can contribute to the assessment of children admitted to hospital with febrile illness and can also create an opportunity for more hospitals in resource-poor settings to participate in clinical trials of interventions to reduce mortality associated with hyperlactatemia. © 2011 The Author.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.